Epirubicin
- Generic Name
- Epirubicin
- Brand Names
- Ellence, Pharmorubicin PFS
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 56420-45-2
- Unique Ingredient Identifier
- 3Z8479ZZ5X
- Background
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
- Indication
For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
- Associated Conditions
- Breast Cancer, Breast Cancer, Stage II, Breast Cancer, Stage III, Colorectal Cancer, Hormone-Refractory Prostate Cancer, Neoplasm of Stomach, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Papillary transitional cell carcinoma of bladder, Recurrent Superficial Bladder Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Carcinoma in situ of urinary bladder
- Associated Therapies
- -
Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma
- Conditions
- First Posted Date
- 2011-04-01
- Last Posted Date
- 2012-06-11
- Lead Sponsor
- Albert Koong
- Registration Number
- NCT01327521
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-10-13
- Last Posted Date
- 2021-05-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 66
- Registration Number
- NCT01220128
- Locations
- 🇬🇧
GSK Investigational Site, Nottingham, United Kingdom
5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-10-07
- Last Posted Date
- 2019-06-19
- Lead Sponsor
- Krankenhaus Nordwest
- Target Recruit Count
- 716
- Registration Number
- NCT01216644
- Locations
- 🇩🇪
Krankenhaus Nordwest, Frankfurt, Germany
Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-09-20
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT01205217
- Locations
- 🇪🇸
GSK Investigational Site, Castellón, Spain
Combination Chemotherapy With or Without Metformin Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-07-22
- Last Posted Date
- 2015-04-24
- Lead Sponsor
- IRCCS San Raffaele
- Target Recruit Count
- 60
- Registration Number
- NCT01167738
- Locations
- 🇮🇹
Istituto Scientifico H. San Raffaele, Milan, Italy
Molecular Triaging of Newly Diagnosed Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-07-09
- Last Posted Date
- 2012-07-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT01159236
Gemcitabine, Cisplatin, Epirubicin, and Capecitabine in Treating Patients With Stage I-II Resectable Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-06-25
- Last Posted Date
- 2017-09-01
- Lead Sponsor
- IRCCS San Raffaele
- Target Recruit Count
- 98
- Registration Number
- NCT01150630
- Locations
- 🇮🇹
Istituto Scientifico H. San Raffaele, Milan, Italy
R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2010-06-22
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 226
- Registration Number
- NCT01148446
- Locations
- 🇮🇹
Ospedale San Sebastiano, Correggio (RE), Italy
🇮🇹Istituto Vito Fazzi, Lecce, Italy
🇮🇹S.C. di Ematologia, Spedali Civili, Brescia, Italy
Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-01-14
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- West German Study Group
- Target Recruit Count
- 3198
- Registration Number
- NCT01049425
- Locations
- 🇩🇪
Bethesda Krankenhaus, Moenchengladbach, Germany
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-12-21
- Last Posted Date
- 2023-03-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 47
- Registration Number
- NCT01036087
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.